Ferring's Testavan launched in UK

Privately-held Swiss drugmaker Ferring Pharmaceuticals today announced the launch of Testavan (transdermal testosterone gel)for the treatment of adult male hypogonadism.

Testavan is a new testosterone replacement therapy designed to restore testosterone levels to a normal range (300–1050 ng/dL) in adult males with hypogonadism.

Male hypogonadism (or low testosterone) is a condition characterized by testosterone deficiency and persistent clinical symptoms. Its incidence varies from 2%–5% of males aged 40 years and above and sufferers can experience adverse physical and psychological effects, with a subsequent reduction in quality of life.Symptoms include decreased libido, erectile dysfunction, fatigue, loss of muscle mass, mood depression, osteoporosis and regression of secondary sexual characteristics.